Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00697541 · ClinicalTrials.gov registry record · Phase 2
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00697541: Completed Phase 2 study, sponsored by Galderma R&D.
NCT00697541 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00697541, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
Primary Outcome
Maximum observed plasma concentration
Interventions
- DRUG 0.18% COL-118 facial gel (1.8 mg brimonidine)
- DRUG 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)
- DRUG Advanced Eye Relief
- DRUG COL-118 facial gel vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
What the finished NCT00697541 record still lists
NCT00697541 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 4 interventions - of which 0.18% COL-118 facial gel (1.8 mg brimonidine) is the first listed.
NCT00697541 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00697541 about?
NCT00697541 is a clinical study titled "Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%". Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
What is the current status of trial NCT00697541?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-05. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00697541?
The interventions under investigation include: 0.18% COL-118 facial gel (1.8 mg brimonidine) (DRUG), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) (DRUG), Advanced Eye Relief (DRUG), COL-118 facial gel vehicle (DRUG).
Who is sponsoring clinical trial NCT00697541?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00697541's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia